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The TSC13/YDL015c gene was identified in a screen for suppressors of the calcium sensitivity of csg2D
mutants that are defective in sphingolipid synthesis. The fatty acid moiety of sphingolipids in Saccharomyces
cerevisiae is a very long chain fatty acid (VLCFA) that is synthesized by a microsomal enzyme system that
lengthens the palmitate produced by cytosolic fatty acid synthase by two carbon units in each cycle of
elongation. The TSC13 gene encodes a protein required for elongation, possibly the enoyl reductase that
catalyzes the last step in each cycle of elongation. The tsc13 mutant accumulates high levels of long-chain bases
as well as ceramides that harbor fatty acids with chain lengths shorter than 26 carbons. These phenotypes are
exacerbated by the deletion of either the ELO2 or ELO3 gene, both of which have previously been shown to be
required for VLCFA synthesis. Compromising the synthesis of malonyl coenzyme A (malonyl-CoA) by inacti-
vating acetyl-CoA carboxylase in a tsc13 mutant is lethal, further supporting a role of Tsc13p in VLCFA
synthesis. Tsc13p coimmunoprecipitates with Elo2p and Elo3p, suggesting that the elongating proteins are
organized in a complex. Tsc13p localizes to the endoplasmic reticulum and is highly enriched in a novel
structure marking nuclear-vacuolar junctions.
The sphingolipids are essential components of eukaryotic
cells that have been implicated in a large number of cellular
processes, including signaling, secretion, Ca21 homeostasis,
and heat stress response (46). Sphingolipids consist of cer-
amide linked through either a glucosyl or phosphodiester bond
to a polar head group. The ceramide moiety is comprised of a
fatty acid joined in amide linkage to a long-chain base (LCB).
In Saccharomyces cerevisiae, the fatty acid is a hydroxylated C26
very long chain fatty acid (VLCFA), the LCB is usually phyto-
sphingosine, and the polar head group is an inositolphosphoryl
moiety that can be further decorated by mannosylation and a
second inositolphosphorylation (Fig. 1; for a review, see refer-
ence 13). The importance of the VLCFAs is highlighted by the
observation that mutants unable to synthesize LCBs are invi-
able, but growth can be restored by second-site mutations in
the SLC1 gene that result in the synthesis of a novel class of
VLCFA-containing inositolglycerophospholipids (36), which
structurally mimic sphingolipids.
The majority of cellular long-chain fatty acids have 16 or 18
carbons and are synthesized by the soluble fatty acid synthase
(FAS) complex that is comprised of two multifunctional sub-
units encoded by the FAS2 (a-subunit) and FAS1 (b-subunit)
genes (28, 52, 53, 65). While the bulk of the cellular fatty acids
are synthesized by FAS, the VLCFAs are synthesized by mem-
brane-associated fatty acid elongating systems. Although fatty
acid elongation has been extensively assayed in microsomal
fractions from mammalian cells, the component enzymes have
resisted purification, and until recently none of the genes en-
coding the enzymes had been identified (reviewed in reference
7). The elongating systems catalyze four reactions, lengthening
the fatty acid by two carbons in each cycle of elongation (Fig.
1). Malonyl coenzyme A (malonyl-CoA), synthesized by acetyl-
CoA carboxylase (ACC), provides the 2-carbon unit both for
de novo long-chain fatty acid synthesis by FAS and for elon-
gation of the long-chain fatty acids to the VLCFAs (Fig. 1). In
contrast to acc1 null mutants (21), strains defective in the
FAS1 or FAS2 gene can be rescued by supplementation of the
growth medium with long-chain fatty acids (44). This indicates
that malonyl-CoA is required for an essential process other
than de novo long-chain fatty acid synthesis, most likely the
elongation of the long-chain fatty acids to the VLCFAs. Con-
ditional mutations of acc1 result in severe membrane pheno-
types at the nuclear envelope-nuclear pore complex under
restrictive conditions (48) and also affect vacuolar membrane
morphology and inheritance, possibly through altered fatty
acylation of the vacuolar membrane protein Vac8p (47).
Despite the ubiquitous presence of VLCFAs and the evi-
dence that they are essential for viability, little is known about
the precise roles of the VLCFAs or about the molecular nature
of the fatty acid elongating enzymes. Candidates for yeast cells
defective in the elongating system were identified in two inde-
pendent screens. These screens took advantage of the obser-
vation that fas2 mutants will grow in medium supplemented
with myristate (C14) as long as this fatty acid can be converted
to the long-chain (C16 and C18) and very long chain (typically
C26) fatty acids by the elongating systems. An additional mu-
tation in the fas2 background rendering cells unable to grow on
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istry, Uniformed Services University of the Health Sciences, 4301
Jones Bridge Road, Bethesda, MD 20814. Phone: (301) 295-3592. Fax:
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FIG. 1. Pathways of fatty acid elongation, LCB, and sphingolipid synthesis in S. cerevisiae. Palmitoyl-CoA is synthesized from acetyl-CoA and
malonyl-CoA by soluble FAS. Palmitoyl-CoA is elongated to a C26 VLCFA by a membrane-associated fatty acid elongating system (A, left branch).
Each cycle of elongation requires four successive reactions and lengthens the growing fatty acid by two carbon units; condensation of malonyl-CoA
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myristate but able to grow on palmitate (C16) identified the
ELO1 gene (14, 59). Subsequently, Elo1p was demonstrated to
be required for efficient elongation of myristate to palmitate.
The ELO1 gene has two structural and functional homologs in
S. cerevisiae, FEN1/ELO2 and SUR4/ELO3. Elo2p is involved
in elongation of fatty acids up to C22 and C24, while Elo3p has
a broader substrate specificity and is required for conversion of
C24 to C26 (37). Neither Elo2p nor Elo3p confers essential
functions by itself; however, elo2D elo3D double mutants are
inviable (37).
The yeast ELO3/SUR4 and/or ELO2/FEN1 genes have also
been identified in a number of other genetic screens (17, 19,
56), including one for suppressors of the Rvs (reduced viability
upon starvation) phenotype of cells lacking the RVS161 gene
(12). Rvs161p is homologous to amphiphysin, a vesicle-associ-
ated protein that participates in endocytosis in mammalian
cells (10, 57, 58), and a mutant allele of rvs161 was recovered
in a screen for endocytic mutants in S. cerevisiae (35). Inter-
estingly, inactivation of the ELO2 or ELO3 gene also bypasses
the requirement for Snc V-SNAREs, further suggesting a role
for VLCFAs in membrane trafficking (11).
VLCFAs are predominantly present in sphingolipids and the
phosphatidylinositol (PtdIns) moiety of glucosylphosphatidyl-
inositol (GPI)-anchored proteins. Sphingolipids in yeast are
assembled in the endoplasmic reticulum (ER) and then mod-
ified and matured in the Golgi; they are major lipid constitu-
ents of the plasma membrane (22). The csg1 and csg2 mutants
are defective in sphingolipid synthesis at the step of inositol-
phosphorylceramide (IPC) mannosylation (Fig. 1); they there-
fore accumulate high levels of IPC, which is correlated with
sensitivity to 10 mM Ca21 in the growth medium (3, 68). Many
mutations that suppress the Ca21 sensitivity of the csg2 mutant
cells reside in genes required for IPC synthesis (15). Interest-
ingly, mutations that suppress the multiple phenotypes of the
rvs161D mutant (named sur mutants) (12, 43, 56) identify genes
that overlap extensively with the collection of sphingolipid
synthesis mutants that were identified as suppressors of the
csg2 Ca21 sensitivity. The SUR1 gene is allelic to CSG1 (3).
The SUR2 gene encodes the hydroxylase that converts dihy-
drosphingosine to phytosphingosine; therefore, sur2 mutants
synthesize ceramides and sphingolipids with dihydrosphin-
gosine rather than phytosphingosine as the LCB (20) (Fig. 1).
The sur4/elo3 mutant is deficient in sphingolipid synthesis be-
cause it makes reduced levels of VLCFA (11, 14, 37, 59). We
identified both the SUR4/ELO3 and FEN1/ELO2 genes in the
csg2 suppressor screen because null mutations in either gene
reduce IPC accumulation and thereby reverse Ca21 sensitivity
of the csg2D mutant. This observation suggested that other
genes required for fatty acid elongation might be identified in
our suppressor collection.
In this report, we identify and characterize the TSC13 gene
and provide evidence that it encodes the enoyl reductase com-
ponent of the elongating system required for the synthesis of
VLCFAs. Tsc13p interacts physically and genetically with
other components of the elongation machinery and is localized
in the ER but is highly enriched at the interface between the
nucleus and the vacuole, marking a novel subdomain of the
ER, the nuclear-vacuolar junction.
MATERIALS AND METHODS
Media, strains, and genetic manipulations. The yeast strains used in this study
are listed in Table 1. Yeast media were prepared and cells were grown according
to standard procedures (54).
Cloning and disruption of the TSC13 gene. The wild-type TSC13 gene was
cloned from a YCp50-based genomic library (45) based on its ability to comple-
ment the ts (temperature-sensitive) phenotype of TDY2050 (tsc13-1 csg2::LEU2)
(2). Two plasmids that conferred temperature resistance were recovered, and
sequence analysis showed that they shared a segment of chromosome IV con-
taining YDL015c and YDL016c. A 1,500-bp NotI and SalI-ended PCR fragment
containing only the YDL015c open reading frame with 370 bp of upstream and
205 bp of downstream flanking sequence was generated using primers 12200 and
12201 (Table 2). The fragment was cloned into pRS316 (55), and the resulting
plasmid (pTSC13-316) was found to complement the ts phenotype of TDY2050.
A disrupting allele of YDL015c/TSC13 was constructed by placing an EcoRI-
ended PCR fragment carrying the TRP1-selectable marker between the MunI
(located 42 bp upstream of the start codon) and EcoRI (located in codon 72)
sites of YDL015c.
Epitope tagging of Tsc13p, Elo2p, and Elo3p. A three-copy Myc epitope
(Myc3) was introduced at the amino terminus of Tsc13p. To accomplish the
tagging, an AvrII site was first introduced after the start codon of TSC13 on
plasmid pTSC13-316 by QuikChange mutagenesis (Stratagene, La Jolla, Calif.),
using the complementary mutagenic primers 12449 and 12450 (Table 2). A
SpeI-ended fragment carrying the Myc3 cassette was generated by PCR using a
Bluescript-based Myc3-containing plasmid (gift of Dan TerBush, Department of
Biochemistry, Uniformed Services University of the Health Sciences) and ligated
into the AvrII site. The NotI-to-XhoI fragment carrying the Myc-tagged TSC13
allele was ligated into pRS426 to generate the MYC-TSC13-426 plasmid. This
Myc-tagged TSC13 allele complemented the temperature sensitivity of the tsc13
mutant, demonstrating that it is functional.
The hemagglutinin epitope (HA)-tagged Elo3p and HA-tagged Elo2p con-
structs were made by inserting SalI-ended restriction fragments extending from
the start codon of Elo2p (or Elo3p) to a site 128 bp (for ELO2) or 1,115 bps (for
ELO3) downstream of the stop codon into the SalI site of plasmid pADH-HA.
The SalI fragments were generated using the PCR primers listed in Table 2 with
vector pCRELO2 (37) as template for ELO2 and strain DTY10A (Table 1)
genomic DNA for ELO3. The resulting plasmids, pADH-HA-ELO2 and pADH-
HA-ELO3, contained the full-length ELO genes with an HA tag fused at the
amino terminus, under control of the ADH1 promoter. The HA-tagged Elo2p
and Elo3p restored normal VLCFA synthesis to the elo2 and elo3 mutants,
respectively.
Disrupting the ELO2 and ELO3 genes. A BamHI-ended PCR fragment ex-
tending from 280 bp upstream of the start codon of ELO3 to 180 bp past the stop
codon was generated using primers 9041 and 9042 (Table 2) and ligated into
pUC19. The resulting plasmid was digested with MscI to release a 140-bp frag-
ment (encoding codons 45 to 91 of ELO3), and an XhoI linker was ligated in at
the deletion junction. A SalI-ended TRP1 fragment was ligated into the XhoI site
to generate the disrupting allele, which was liberated from plasmid pUC19 by
digestion with KpnI and SalI. For the ELO2 gene, a BamHI-ended PCR frag-
ment extending from 160 bp upstream of the start codon to 170 bp past the stop
codon was generated using primers 9043 and 9044 (Table 2) and ligated into
pUC19. An EcoRI-ended TRP1 fragment was ligated between the MunI sites of
ELO2, thereby replacing codons 92 to 183 with the selectable marker. The
disrupting allele was liberated from the plasmid by digestion with KpnI and SalI.
Ceramide and LCB analysis. Ceramides were extracted and analyzed by thin-
layer chromatography (TLC) as previously described (20). LCBs were extracted,
separated by TLC, and visualized using ninhydrin as described elsewhere (2).
Fatty acid analysis. Cells (5 3 108) in mid-logarithmic-stage growth were
harvested and resuspended in 100 ml of distilled H2O along with 25 mg of linoleic
with the acyl-CoA substrate, reduction of the 3-ketoacyl-CoA, dehydration of the 3-hydroxyacyl-CoA, and reduction of the trans-2,3-acyl-CoA.
Although the intermediates and the product of the elongation cycle are shown as CoA derivatives, this has not yet been experimentally confirmed.
The organization of the elongating enzymes with respect to each other is unknown. The LCBs are synthesized by the pathway shown in the right
branch of panel A; the pathway for the conversion of ceramide to mature sphingolipids is shown in panel B.
VOL. 21, 2001 THE TSC13 GENE IS REQUIRED FOR VLCFA SYNTHESIS 111
acid (18:2) as an internal standard for extraction of the fatty acids. Fatty acid
methyl esters were prepared by HCl methanolysis as previously described (59),
resuspended in 50 ml of hexane, and stored at 220°C. Gas chromatography (GC)
was performed using a Varian 3400CX chromatograph and a Supelcowax TM10
column, and data were collected and analyzed using Class-VP Chromatography
Data System version 4.1 software (Shimadzu Scientific Instruments) as described
elsewhere (6).
Elongase assays. Microsomes were prepared from the wild-type or tsc13-1
mutant cells as previously described (18). By using the purified microsomes for
the elongation assays, the background of acyl-CoA-independent incorporation of
malonyl-CoA into fatty acids (as a result of the soluble FAS activity) was reduced
to less than 10% of the acyl-CoA-dependent incorporation of malonyl-CoA into
fatty acids. Total elongase activity was measured in a volume of 200 ml containing
50 mM Tris (pH 7.5), 1 mM MgCl2, 150 mM Triton X-100, 1 mM NADPH, 1 mM
NADH, 10 mM b-mercaptoethanol, 40 mM acyl-CoA acceptor (either palmitoyl-
CoA, stearoyl-CoA, or eicosanoyl-CoA), and 60 mM [2-14C]malonyl-CoA (0.05
mCi/ml) at 37°C. The reaction was initiated by the addition of 0.3 to 1.0 mg of
microsomal protein. Protein concentrations were determined using the Bio-Rad
protein assay reagent (Bio-Rad Laboratories, Hercules, Calif.). For assays of
only the condensing activity, the NADPH and NADH were omitted. At various
times, the reaction was terminated by adding 200 ml of 5 M KOH–10% methanol
MeOH and heating at 80°C for 1 h. Following addition of 200 ml of 10 N H2SO4,
fatty acids were recovered by two 1.5-ml extractions into hexane. The extracted
fatty acids were resolved by silica gel TLC using hexane-diethyl ether-acetic acid
(30:70:1) as the developing solvent. The radiolabeled fatty acids were detected
and quantified using a PhosphorImager SI (Molecular Dynamics, Inc., Sunny-
vale, Calif.).
Immunoprecipitation. Microsomes were prepared from strains containing
Tsc13p-Myc and either Elo2p-HA or Elo3p-HA as previously described (18).
The microsomes were solubilized at 1 mg/ml with 2 mM sucrose monolaurate
(Roche Diagnostics, Indianapolis, Ind.) for 10 min, and the high-speed (105 3 g,
30 min) supernatant was collected. The supernatant (150 ml) was incubated with
3 ml of the precipitating antibody for 2 h and then with 20 ml of protein
A-Sepharose (125 mg/ml; Sigma) for 2 h. The precipitates were washed three
times with 600 ml of 50 mM HEPES (pH 7.5) and resuspended in 150 ml of
sodium dodecyl sulfate (SDS) loading buffer; a 10-ml sample was subjected to
SDS-polyacrylamide gel electrophoresis (PAGE) on an 8% gel. Following trans-
fer of the separated proteins to nitrocellulose, the blots were blocked in 0.1 M
Tris (pH 7.5)–0.15 M NaCl–0.1% Tween 20–5% dry milk. Tsc13p-Myc was
detected with horseradish peroxidase (HRP)-conjugated monoclonal anti-Myc
TABLE 1. Yeast strains used in this study
Strain Genotype
TDY2037...............................................................................................................mata lys2 ura3-52 trp1D leu2D
TDY2038...............................................................................................................mata csg2::LEU2 lys2 ura3-52 trp1D leu2D
TDY2050...............................................................................................................mata tsc13-1 csg2::LEU2 ade2-101 ura 3-52 trp1D leu2D
TDY2055...............................................................................................................mata elo2::URA3 csg2::LEU2 his4-619 ura3-52 trp1D leu2D lys2
TDY2056...............................................................................................................mata elo3::URA3 csg2::LEU2 his4-619 ura3-52 trp1D leu2D lys2
TDY2051...............................................................................................................mata tsc13-1 ade2-101 ura3-52 trp1D leu2D lys2
TDY2053...............................................................................................................mata elo2::URA3 his4-619 ura3-52 trp1D leu2D
TDY2054...............................................................................................................mata elo3::URA3 his4-619 ura3-52 trp1D leu2D
TDY2057...............................................................................................................mata elo2::TRP1 tsc13-1 ade2-101 ura3-52 trp1D leu2D lys2
TDY2058...............................................................................................................mata elo3::TRP1 tsc13-1 ade2-101 ura3-52 trp1D leu2D
FY1679a ................................................................................................................mata/a ura3-52/ura3-52 leu2D1/1trp1D63/1his3D200/1
DTY10A................................................................................................................mata leu2-3,112 can1-100 ura3-1 ade2-1 his3-11,15 (TRP11)
DTY004.................................................................................................................mata elo2::HIS3 leu2-3, 112 can1-100 ura3-1 ade2-1
SEY002b ................................................................................................................mata acc1ts (mtr7) lys? leu2 ade2 his3
SEY003c ................................................................................................................mata aac1cs leu2-3,112 ura3-1 ade2-1 his3-11,15 can1-100
SEY004d ................................................................................................................mata acc1-2150 lys? leu2 ade2 ura3
BJ9367e..................................................................................................................mata pep3::TRP1 ura3-52 leu2-D1 his3-D200 trp1
RW9065f................................................................................................................mata ade2 his3-D200 lys2-801 ura3-52 met? {pGAL1-HMG1}
CSY10A ................................................................................................................mata elo3::HIS3 leu2-3,112 can1-10 ura3-1 ade2-1
CSY10Aelo2/HA-ELO........................................................................................mata elo2::HIS3 can1-100 ura3-1 ade2-1 {pADH1-HA-ELO2-LEU2}
CSY10Aelo3/HA-ELO3......................................................................................mata elo3::HIS3 can1-100 ura3-1 ade2-1 {pADH1-HA-ELO3-LEU2}
CSY10Aelo2/GFP-ELO2....................................................................................mata elo2::HIS3 can1-100 ura3-1 ade2-1 {pGAL1-GFP-ELO2-LEU2}
a Provided by J. Hegemann.
b Provided by A. Tartakoff.
c Provided by H. Klein.
d Provided by E. Schweizer.
e Provided by E. Jones.
f Provided by R. Wright.
TABLE 2. Sequences of oligonucleotides used for cloning, tagging, and disrupting TSC13, ELO2, and ELO3
Oligonucleotide Sequencea
12201.........................................................................................................59-GGCCGCGGCCGCGGGCAACTTAGATTTATCCG-39
12200.........................................................................................................59-GGCCGTCGACGTACTTACATATTTGCATAGT-39
12449.........................................................................................................59-TTTGAATTTAATTTGAAA-ATGCCTAGGATCACCATAAAAAGC-39
12450.........................................................................................................59-GCTTTTTATGGTGATCCTAGGCATTTTCAAATTAAATTCAAA-39
ELO2F-SAL1 ..........................................................................................59-CGCAGGTCGACCATGAATTCACTCGTTACTC-39
ELO2R.....................................................................................................59-TTCACACAGGAAACAG-39
ELO3F-SAL1 ..........................................................................................59-CGCAGGTCGACCATGAACACTACCACATCTAC-39
ELO3R.....................................................................................................59-GTCCTGCGATTTTATTCG-39
9041...........................................................................................................59-GGCCGGATCCTCCAGACTGTGAATAAAC-39
9042...........................................................................................................59-GGCCGGATCCGTATCACTACTCCTCACTGT-39
9043...........................................................................................................59-GGCCGGATCCGTACGTATTCACATGTCCTG-39
9044...........................................................................................................59-GGCCGGATCCTAGACATGACTGTCGAAAGG-39
a Restriction sites referred to in the text are underlined.
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antibodies (from InVitrogen) at 1/5,000. Elo2p-HA and Elo3p-HA were de-
tected using HRP-conjugated monoclonal anti-HA antibodies (from Boehringer
Mannheim) at 1/1,000. The bound antibodies were detected by the ECL Western
blotting detection system (Amersham Pharmacia Biotech).
Construction of Tsc13p-GFP by chromosomal fusion. Plasmid pMK199-GA5-
yEGFP-kanMX6 containing a five-copy glycine-alanine (GA5) linker fused to
yeast enhanced green fluorescent protein (yEGFP) and the kanMX6 resistance
marker, was used as the template for PCRs to amplify the integration cassette
(64). Using the two primers pYDL015cGA53 and pYDL015cMX64 (Table 3) a
2,550-bp fragment was generated by PCR. The upstream primer contained 30
nucleotides homologous to the GA5 linker 59 to the yEGFP sequence of the
template plasmid and 46 nucleotides corresponding to the 39 end of the
YDL015c coding sequence (excluding the stop codon). The downstream primer
contained 26 nucleotides homologous to the kanMX6 sequence and 47 nucleo-
tides homologous to the chromosomal sequence downstream of the YDL015c
reading frame. PCR amplification was performed in a 25-ml standard reaction
mix containing 13 Ex-Taq buffer (as specified by the supplier [Boehringer,
Mannheim, Germany]), 300 ng of plasmid DNA, 100 pmol of each primer per ml,
and 2.5 mM deoxynucleoside triphosphates. After the initial denaturation step at
94°C for 5 min, the PCR was started by the addition of 2 U of Takara Ex-Taq
polymerase (Boehringer). The fragment was amplified during eight cycles of 30 s
at 94°C, 30 s at 54°C, and 150 s at 72°C, 25 cycles of 30 s at 94°C and 180 s at 72°C,
and a final elongation step of 12 min at 72°C. The resulting PCR fragment was
purified by using a QIAquick PCR purification kit (Qiagen). About 0.5 to 1 mg
of the PCR product was used for yeast transformation into diploid wild-type
strain FY1679, and transformants were selected on plates containing Geneticin
(G418; 200 mg/ml; Calbiochem). After restreaking on G418 plates, positive
transformants were verified by colony PCR using the primers pYDL015c3,
kanMX4, and pGFP44 (Table 3). Growth tests verified that the C-terminal
chromosomal fusion of TSC13 with green fluorescent protein (GFP) rendered
cells fully viable and phenotypically indistinguishable from wild-type cells.
Construction of Opi3p-GFP by chromosomal fusion. The Opi3p-GFP (a bona
fide ER protein; phospholipid-N-methyltransferase 24) chromosomal fusion was
constructed and verified as described above for Tsc13p-GFP, using the primer
pairs listed in Table 3. PCR products were transformed into the diploid wild-type
strain FY1679, and transformants were selected on YPD plates containing Ge-
neticin (200 mg/ml). After restreaking on G418 plates, positive transformants
were verified by colony PCR using the primers pOP133, kanMX4, and pGFP44
(Table 3).
Construction of Elo2p-GFP. The GFP-fused Elo2p construct was made by
inserting the SalI-flanked restriction fragment containing ELO2 (described
above) into the SalI site of vector pGAL1-GFP. The resulting plasmid encoded
a chimeric protein consisting of a GFP domain fused in frame to the amino
terminus of the full-length Elo2 protein. The GFP-Elo2p fusion repaired the
altered VLCFA phenotype associated with the elo2 mutant.
Fluorescence microscopy. Microscopy was performed on a Leica TCS 4d
confocal microscope equipped with an Ar-Kr laser, an acousto-optical tunable
filter for laser wavelength selection and attenuation, a 500-nm beam splitter/
dichroic mirror, and a 525/50-nm band-pass filter for GFP detection. For double-
labeling experiments with the vacuolar dye FM4-64 [N](3-triethylammoniumpro-
pyl)-4-(p-diethylaminophenylhexatrienyl)] pyridinium dibromide Molecular
Probes, Eugene, Oreg.), an additional dichroic 525-nm beam splitter was used in
the emission path, and 525/50-nm band-pass and 590-nm long-pass filters were
used for simultaneous GFP and FM4-64 detection, respectively. The objective
was a 1003/1.4-numerical-aperture lens, and transmission was recorded using
differential interference contrast (DIC; Nomarski) optics. Images were routinely
acquired using 4-8 3 line averaging mode (ScanWare; Leica Microsystems).
Cells were stained with FM4-64 (Molecular Probes) (63) and immobilized for
microscopic inspection as described elsewhere (26). Images were edited using
Adobe Photoshop 5.0 and NIH Image 1.62.
RESULTS
Isolation of the tsc13 mutants and cloning of the TSC13
gene. The csg2D mutant fails to mannosylate IPC and conse-
quently accumulates high levels of IPC (3, 68). These lipid
alterations result in a Ca21-sensitive phenotype; therefore,
suppressor mutants that are able to grow on Ca21 identify
genes required for IPC synthesis. Twenty-one TSC comple-
mentation groups were identified in a screen for mutants that
had acquired a single mutation that conferred both suppres-
sion of Ca21 sensitivity and temperature sensitivity (2). Ge-
netic linkage analysis demonstrated that in most cases both
phenotypes were caused by the same mutation. Three inde-
pendent mutations in the TSC13 gene were identified in this
screen. The TDY2050 mutant, containing the tsc13-1 allele,
was chosen for further analysis and was found to have pheno-
types (Fig. 2) similar to those observed in mutants lacking
either the ELO2 or ELO3 gene. As shown in Fig. 2, disruption
of either the ELO2 or the ELO3 gene also suppressed the
Ca21-sensitive phenotype of the csg2D mutant grown to an
optical density at 600 nm (OD600) of 0.1 on SD minimal me-
dium. On rich (YPD) medium, the elo3 csg2 double mutant
grew poorly at 37°C and failed to grow at 26°C. The ts pheno-
type caused by the tsc13-1 mutation was more severe in strains
lacking the CSG2 gene (Fig. 2). Furthermore, disruption of
either the ELO2 or ELO3 gene exacerbated the ts phenotype
caused by the tsc13-1 mutation (Fig. 2). The genetic interac-
tions between tsc13 and elo2 and with elo3 suggested that
Tsc13p might be required for VLCFA synthesis and function in
the same pathway as Elo2p and Elo3p.
The wild-type TSC13 gene was cloned based on its ability to
complement the ts phenotype of the TDY2050 (tsc13-1) mu-
tant. Subcloning experiments demonstrated that the YDL015c
open reading frame was responsible for complementation (see
Materials and Methods). A URA3-marked wild-type YDL015c
allele was found to be tightly linked to the tsc13-1 mutant
allele, demonstrating that the complementing YDL015c gene
corresponds to the wild-type TSC13 gene. A diploid heterozy-
gous for the tsc13::TRP1 disruption (see Materials and Meth-
ods) was sporulated, and tetrads were dissected. Each tetrad
gave rise to two viable tryptophan-requiring spore colonies,
confirming the previously reported (60) finding that the
TSC13/YDL015c gene is essential for viability.
TABLE 3. Sequences of oligonucleotides used for constructing Tsc13p-GFP and Opi3p-GFP
Oligonucleotide Sequencea
pYDL015cGA53 .............................59-caaaaagtatcataccagaagagcattcttgattccatttgtatttGGAGCAGGTGCTGGTGCTGGTGCTGGAGCA-39
pYDL015cMX64 ............................59-gctaatatctctttaccttgcatttgggcatgttgcaaacaggaggatcaATCGATGAATTCGAGCTCGTTTAAAC-39
pYDL015c3 .....................................59-gtaacgctaagatccgtgtc-39
pOPI3GA53 ....................................59-ccttttactgccatgatctacgctaaccgtgataaggccaaaaagaatatgGGAGCAGGTGCTGGTGCTGGTGCTGGAGCA-39
pOPI3MX64....................................59-cggtaatagcataggcttctaacattatagaatatatagaaatagagcactcaATCGATGAATTCGAGCTCGTTTAAAC-39
pOPI33.............................................59-ggatgagagagtcaccggc-39
kanMX-reverse4 .............................59-ctagcggatctgccggtagag-39
pGFP44............................................59-ggtcaatttaccgtaagt-39
a Lowercase, coding gene sequence; italic, 39 untranslated region gene sequence; uppercase lightface, GA5 linker sequence (30 bp); uppercase boldface, kanMX6
sequence (26 bp); underlined, stop codon.
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Tsc13p is evolutionarily conserved and has similarity to a
steroid reductase. The TSC13 gene is predicted to encode a
protein of 310 amino acids with significant homology (35%
identity, 50% similarity) over its entire length to evolutionarily
conserved proteins of previously unknown function called the
SC2 proteins (Fig. 3a). The SC2 gene, originally identified in a
screen for cDNAs that encode rat synaptic glycoproteins, was
found to be expressed at high levels in the brain and at lower
levels in other tissues (23). The pattern of hydrophobicity and
the positions of potential membrane-spanning domains in the
Tsc13p/SC2 proteins have been conserved throughout evolu-
tion (Fig. 3b), and Tsc13p behaves as an integral membrane
protein (discussed below). As previously noted (23) for the
SC2 protein, Tsc13p has homology in the carboxy-terminal 150
amino acids (29% identical, 45% similar) to steroid-5-a-reduc-
tase, which catalyzes the reduction of testosterone to dihy-
drotestosterone. Steroid-5-a-reductase, like the enoyl reduc-
tase of the fatty acid elongating system, catalyzes the reduction
of a double bond that is a,b to a carbonyl group. The discovery
that the tsc13 mutants are deficient in VLCFA synthesis raised
the possibility that Tsc13p catalyzes the last step in each cycle
of elongation, reduction of the trans-2,3-enoyl-CoA interme-
diate (Fig. 1).
The tsc13 mutant accumulates LCBs as well as ceramides
that have fatty acids with chain lengths of less than 26 car-
bons. In contrast to wild-type cells, the elo2D and elo3D mutant
cells accumulated high levels of LCBs (Fig. 4 and reference
37). The tsc13 mutant also accumulated free LCBs, and this
phenotype was even more severe in tsc13-1 elo2D and tsc13-1
elo3D double mutants than in the single mutants (Fig. 4). The
accumulated LCBs, primarily phytosphingosine but also dihy-
drosphingosine and small amounts of 3-ketosphinganine, are
normal intermediates in the LCB biosynthetic pathway. Thus,
the mutant phenotype may reflect reduced partitioning of the
LCBs into ceramides and sphingolipids because of a defect in
VLCFA synthesis in the mutants.
A significant fraction of the ceramides from elo2D, elo3D,
and tsc13-1 mutant cells displayed reduced TLC mobilities
indicative of increased hydrophilicity in comparison to the
C-ceramide (containing phytosphingosine and a-OH-C26)
present in wild-type cells (Fig. 5a). The accumulation of the
relatively hydrophilic ceramides was more severe in the tsc13-1
elo2D and tsc13-1 elo3D double mutants than in the single
mutants. The mobility of these ceramide species suggested that
they were likely to be hydroxylated on the a-carbon of the fatty
acid and to contain fatty acids of chain lengths shorter than
C26. To test this hypothesis, we disrupted the SCS7 gene en-
coding the enzyme required for the a-hydroxylation of the
VLCFA (20, 34) and compared the ceramides present in the
single and double mutants. The increased mobility of the cer-
amides in scs7D elo2D and scs7D elo3D double mutants con-
firmed that Scs7p (Figure 5b) hydroxylates the ceramides in
the mutants.
The unhydroxylated ceramides in the scs7D elo2D and scs7D
elo3D double mutants also displayed altered ceramide mobili-
ties consistent with increased hydrophilicity. To investigate
whether this was indeed due to shorter chain lengths of the
fatty acids, the ceramides were purified from the TLC plates
and hydrolyzed, and the methyl esters of the liberated fatty
acids were analyzed by GC-mass spectrometry. As shown in
Figure 5c, the mutant strains accumulated ceramides contain-
ing fatty acids with less than 26 carbons. The net ceramide
levels do not appear to be appreciably lower than in wild-type
cells (Fig. 5a). However, while the C24-containing ceramides
are inositolphosphorylated, the resulting IPCs are not manno-
sylated (37). Furthermore, the hydrophilic ceramides contain-
ing fatty acids with chain lengths shorter than C24 apparently
are not inositolphosphorylated since hydrophilic IPCs do not
accumulate in the elongase mutants (data not shown). Taken
together, these data suggest that the accumulation of LCB in
the elo2, elo3, and tsc13 mutants may reflect, at least in part,
reduced incorporation of the LCBs into the mature sphingo-
lipids, presumably due to impaired availability of VLCFAs.
The tsc13 mutant has a defect in VLCFA synthesis. The fatty
acid composition of the mutant cells confirmed a deficiency in
VLCFA synthesis. The tsc13 mutant cells had greatly (;25%)
reduced levels of 26:0 (Fig. 6a), which is the predominant
species found in wild-type cells, and an approximate fourfold
increase in the 24:0 intermediate species. By comparison, the
elo3D mutant lacked 26:0 and accumulated high levels of C22
and C20 intermediates, while the elo2D mutant was deficient in
the synthesis of all VLCFA species. The tsc13, elo2D, and elo3D
mutants also exhibited striking differences from wild type in
their hydroxy fatty acid profiles (Fig. 6b). In particular, the
three mutants accumulated high levels of OH-16:0, and the
elo2D mutant also accumulated significant levels of OH-18:0.
OH-C16 and OH-C18 fatty acids were not detected in wild-type
cells. The three mutants also displayed high levels of OH-24:0,
a minor species in the wild type, and reduced levels of OH-26:0
(particularly elo3), which is the most abundant hydroxylated
fatty acid in the wild type. As indicated previously, the elo3
FIG. 2. A mutation in the TSC13 gene suppresses the Ca21 sensi-
tivity of the csg2D mutant and confers temperature-sensitive lethality.
The elo2D and elo3D mutations also suppress the Ca21 sensitivity of
the csg2D mutant, and the tsc13-1 mutation displays synthetic growth
phenotypes with the elo2D and elo3D mutations. The indicated strains
(Table 1) were grown in SD medium to an OD600 of 0.1 and then
diluted 1/100 into the wells of a microtiter plate. The cells were trans-
ferred to plates containing the indicated medium with or without 50
mM CaCl2 (Ca), and the plates were incubated at 26°C for 3 days or
37°C for 2 days.
114 KOHLWEIN ET AL. MOL. CELL. BIOL.
mutant accumulated high levels of 20:0 and 22:0, which was not
found in either the tsc13 or elo2 mutant.
Previously, a conditional mtr7 mutant, defective in ACC
(ACC1) activity was found to contain significantly reduced
levels of C26 fatty acid (21, 48, 49). It was suggested that
malonyl-CoA-dependent chain elongation was limiting in this
mutant under restrictive conditions. Consistent with a role for
Tsc13p in fatty acid elongation, mtr7 tsc13-1 double mutants
were nonviable even under conditions permissive for both sin-
gle mutants. A similar synthetic lethality was observed between
elo2 mtr7 and elo3 mtr7 double mutants; synthetic lethality of
elo2, elo3, and tsc13-1 with acc1 mutants was not allele specific
(data not shown). ACC activity can be specifically inhibited by
the polyketide fungicide soraphen A (48, 50, 62). The tsc13,
elo2, and elo3 mutants were found to be hypersensitive to
soraphen A (data not shown). Taken together, these data sug-
gest that reduced production of malonyl-CoA in acc1 mutants
or in the presence of soraphen A in addition to compromised
fatty acid elongation activity is detrimental to the cell.
The tsc13 mutant has reduced fatty acid elongation activity.
The TSC13 gene, unlike the ELO2 and ELO3 genes, is essen-
tial for viability, and there are no TSC13 homologous genes in
the S. cerevisiae genome. Elo2p and Elo3p have partially re-
dundant functions and are believed to participate in the same
step of the elongation cycle, with preferences for acyl-CoA
substrates of different chain lengths (37, 59). However, Tsc13p
is likely to be required for catalyzing a step in each cycle of
fatty acid elongation for acyl-CoA substrates of all chain
lengths. To address which step of elongation might be affected
FIG. 3. The Tsc13p and SC2 proteins are members of an evolu-
tionarily conserved family of proteins. (a) Alignment of rat, human,
Arabidopsis thaliana (arab), Schizosaccharomyces pombe (pombe), and
S. cerevisiae (cere) homologs. The tsc13-1 mutant allele has a substi-
tution of lysine for the highly conserved glutamine at residue 81 of the
S. cerevisiae protein (marked with an asterisk). (b) All of the Tsc13p/
SC2 protein homologs have similar hydrophilicity profiles. Segments of
the proteins with the potential to span the membrane are indicated in
black.
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by the tsc13 mutation, microsomes were prepared from the
tsc13 mutant cells and assayed for elongase activity in vitro. For
these experiments, the incorporation of [2-14C]malonyl-CoA
into elongated acyl-CoA products was measured. The first step
of the elongation cycle is the condensation of malonyl-CoA
with an acyl-CoA (e.g., palmitoyl-CoA) to form a 3-ketoacyl-
CoA intermediate (Fig. 1). Omitting pyridine nucleotide from
the assay mix prevents the reduction of the 3-ketoacyl-CoA
intermediate, thereby allowing the first step of elongation
(condensation) to be measured. The condensation activity
measured in wild-type or tsc13-1 microsomes was very similar
when palmitoyl-CoA (or eicosanoyl-CoA) was used as a sub-
strate (Fig. 7a). However, the total elongation activity mea-
sured using microsomes from the tsc13 mutant cells was about
50% of that in wild-type microsomes for each of the acyl-CoA
substrates tested (Fig. 7a). These results indicate that Tsc13p
catalyzes a step in elongation subsequent to the condensation
step.
To investigate the elongation defect in the tsc13-1 mutant
further, time courses of the condensation reaction and the total
elongation reaction were conducted, and the products were
analyzed by TLC using conditions that resolved the four inter-
mediates of fatty acid elongation. Elongation intermediates did
not accumulate during the elongation reactions catalyzed by
the wild-type microsomes (Fig. 7b), which is consistent with
previous studies of the rat microsomal elongating systems dem-
onstrating that the condensation reaction is rate limiting (5).
However, when microsomes prepared from the tsc13 mutant
were used in the assay, accumulation of the trans-2,3-stearoyl
and 3-hydroxystearoyl intermediates was observed. This is con-
sistent with the defect in Tsc13p causing reduced activity of the
trans-2,3-enoyl-CoA reductase leading to accumulation of the
trans-2,3-stearoyl-CoA. Because the dehydratase step of elon-
gation is reversible (25), accumulation of trans-2,3-stearoyl-
CoA would be expected to cause the observed accumulation of
3-hydroxystearoyl-CoA as well. Based on its homology to ste-
roid-5-a-reductase, Tsc13p may directly catalyze the reduction
of the enoyl intermediate in each cycle of fatty acid elongation.
Tsc13p coimmunoprecipitates with Elo2p and Elo3p. The
enzymes responsible for fatty acid elongation have not yet been
purified, and virtually nothing is known about their molecular
organization. For example, it is not known whether they asso-
ciate into a complex that processively elongates fatty acids, or
whether the acyl-CoA intermediates diffuse from one mem-
brane-associated elongating enzyme to the next. To address
whether Tsc13p associates with Elo2p and Elo3p, we at-
tempted protein coimmunoprecipitation. The plasmid carrying
the Myc-tagged TSC13 allele (MYC-TSC13-426) was trans-
formed into TDY2058 (Table 1) independently or in combi-
nation with a plasmid carrying either HA-tagged Elo3p or
HA-tagged Elo2p. Tsc13p, Elo2p, and Elo3p (as their Myc- or
HA-tagged versions, respectively) were all found to display
detergent solubilization properties indicating that they are
tightly associated integral membrane proteins (data not
shown). Antibodies to the Myc epitope coimmunoprecipitated
Elo2p-HA or Elo3p-HA along with Tsc13p-Myc, and vice
versa (Fig. 8), from solubilized microsomal preparations.
These data suggest that Tsc13p forms complexes with Elo2p
and with Elo3p. It is not yet known whether Elo2p and Elo3p
coexist in the same Tsc13p-containing complexes. Although it
appears that Elo3p is more abundant than Elo2p (Fig. 8, lower
panel, compare lanes 1 and 2), the tagged proteins are being
expressed by the ADH1 promoter on plasmids. Furthermore,
the strain (TDY2058) harboring the tagged proteins lacks the
wild-type ELO3 gene but has the wild-type ELO2 gene, and
the level of either tagged protein is reduced when the corre-
sponding endogenous wild-type protein is present (data not
shown).
Tsc13p localizes in the ER and is enriched at sites of vacu-
ole-nuclear envelope interaction. Based on cell fractionation of
the epitope-tagged proteins, Elo2p, Elo3p (reference 14 and
this study), and Tsc13p are present in the microsomal mem-
brane fraction, suggesting localization to the ER. To analyze
Tsc13p subcellular localization in greater detail, Tsc13p was
C-terminally tagged with GFP by chromosomal fusion. The
localization of Tsc13p-GFP, demonstrated to be a functional
protein, revealed a perinuclear and peripheral staining consis-
tent with association with the ER (Fig. 9A). A similar pattern
of staining was observed in cells expressing a chromosomal
Elo3p-GFP fusion (Fig. 9B, 2a and c). Elo2p-GFP, expressed
from an episomal plasmid under control of the GAL1 pro-
moter, showed a staining pattern indistinguishable from that of
Elo3p-GFP (Fig. 9B, 3a and c), and Opi3p-GFP, which was
used as a control for the ER (24) (Fig. 9B, 4a and c). Inter-
estingly, however, in addition to the typical nuclear rim-ER
staining exhibited by Elo2p, Elo3p, or Opi3p, Tsc13p-GFP was
highly enriched in structures reminiscent of the recently de-
scribed nuclear-vacuolar junctions (39) that are contact sites
FIG. 4. The tsc13-1, elo2D, and elo3D mutants accumulate high
levels of free LCBs. LCBs were extracted from 10 OD600 units of the
indicated cells, separated by TLC, and visualized by ninhydrin staining.
The LCB standards sphingosine (SPH), dihydrosphingosine (DHS),
phytosphingosine (PHS), and 3-ketosphingosine (3-KS) were spotted
in lane 1 (positions indicated). The ninhydrin-reactive species that
migrate just below DHS and near the origin (indicated by the arrows)
are phosphatidylserine (PS) and phosphatidylethanolamine (PE).
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between the nucleus and the vacuole (Fig. 9A). The intensity of
the Tsc13p-GFP signal and enrichment of Tsc13p to the sites
of nuclear-vacuolar interaction increased during growth on
complete medium. Furthermore, vesicles that contain Tsc13p-
GFP in the membrane appeared closely associated to, or even
enclosed by, FM4-64-labeled vacuolar membrane structures
(Fig. 9A). These structures appeared more frequently as cells
entered stationary phase.
FIG. 5. The tsc13-1, elo2D, and elo3D mutants accumulate ceramides with chain lengths shorter than C26. (a) Ceramides were extracted from
10 OD600 units of the indicated cells, separated by TLC, and visualized by charring. Bovine ceramide type III (consisting of sphingosine and C16
fatty acid) and type IV (consisting of sphingosine and a-OH-C16 fatty acid) standards are present in lanes 1 and 2. The predominant ceramide in
wild-type cells (C-ceramide) consists of phytosphingosine and a-OH-C26 fatty acid. The D-ceramide is presumed to contain dihydroxy-VLCFA and
phytosphingosine. (b) Ceramides from the indicated mutants were analyzed as for panel a. Deletion of SCS7 prevented hydroxylation of the fatty
acid on the a-carbon, causing the ceramides to become more hydrophobic. (c) Ceramides purified from wild-type (wt) and tsc13-1, elo2D, and elo3D
mutant cells were hydrolyzed to generate fatty acid methyl esters, and the extracted methyl esters were subjected to GC-mass spectrometry. The
hydrophilic ceramides in the mutants (purified from the region of the TLC below C-ceramide as indicated by the bracket in panel a) contained
a-hydroxylated fatty acids with chain lengths of less than C26. A mock extraction of the silica gel was conducted, and the background spectrum was
subtracted.
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Although Elo2p, Elo3p, and Tsc13p appear to be involved in
the same pathway and may physically interact, as demonstrated
above, their localization patterns are different. The codon ad-
aptation indices for Elo2p (0.239) and Elo3p (0.372) are sim-
ilar to that of Tsc13p (0.240 98). To analyze whether appar-
ently homogeneous ER staining of Elo2p or Elo3p is due to
increased abundance that obscures a specific labeling pattern,
we have modulated expression levels of one of these proteins
by virtue of GAL1-controlled expression. Figure 10A shows a
time course of derepression of a plasmid-borne Elo2p-GFP
after a shift from glucose to galactose medium. Even at very
low expression levels, Elo2p-GFP distribution in the ER was
indistinguishable from the wild-type pattern; under no condi-
tions did we observe a pattern reminiscent of Tsc13p-GFP,
suggesting that Tsc13p localization to nuclear-vacuolar junc-
tions does not depend on Elo2p.
Tsc13p-GFP localization is independent of Elo2p and Elo3p.
To further determine whether Tsc13p localization is depen-
FIG. 6. The elongase mutants are deficient in synthesis of VLCFAs and accumulate hydroxylated fatty acids with chain lengths shorter than C26.
Fatty acid methyl esters were derived from wild-type (wt) and tsc13-1, elo2D, and elo3D mutant cells and analyzed by GC. The mass of each fatty
acid species per cell was determined by comparison to an internal standard that was added to the cells prior to the methanolysis reaction. (a) Mass
of total nonhydroxylated fatty acids in cells (log scale); (b) mass of total hydroxylated fatty acids.
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dent on the presence of either Elo2p or Elo3p, Tsc13p-GFP
distribution was analyzed in elo2 or elo3 mutants, respectively
(elo2 elo3 double mutants are nonviable). Labeling of cells with
FM4-64 revealed that the vacuolar morphology was drastically
altered in elo2 and elo3 mutants and displayed a multilobed
structure, reminiscent of vac8 mutants (47, 66) (Fig. 10B).
Despite the high fragmentation of vacuoles into smaller vesi-
cles, the polarity of Tsc13p localization was still maintained
and the protein was still present at nuclear-vacuolar junctions.
No alteration of the Tsc13p distribution was observed in these
mutants, compared to wild type, suggesting that neither Elo2p
is Elo3p are required for polarized Tsc13p localization at the
nuclear-vacuolar junction.
Expression of Tsc13p-GFP does not result in the formation
of karmellae. Some ER-resident proteins, e.g., Hmg1p (hy-
droxymethylglutaryl-CoA reductase), when overexpressed lead
to the formation of karmellae, which are multiple stacks of ER
membrane, highly enriched in these proteins (27, 40, 67). As a
consequence, karmellae induced by Hmg1p-GFP appear as
very bright structures on the surface of the nucleus, at regions
located opposite the vacuole (27). As shown in Fig. 11A, the
localization of karmellae, albeit similar in appearance on the
nuclear surface, is clearly different from the localization pat-
tern of Tsc13p-GFP in the nuclear-vacuolar contact sites. In
addition, ER membranes labeled with DiOC6 (27) in strains
expressing Tsc13p-GFP appeared indistinguishable from wild
type, demonstrating that GFP tagging of Tsc13p does not re-
sult in the formation of karmellae. This was further confirmed
by electron microscopy demonstrating lack of any membrane
proliferations in Tsc13p-GFP-expressing strains (data not
shown).
The polarized localization of Tsc13p-GFP depends on the
presence of vacuoles. Depending on growth phase, in the pres-
ence of nonfermentable carbon sources, or in elo2 and elo3
mutants, yeast vacuoles may split up into multiple smaller
vesicles. Under these conditions, Tsc13p-GFP was consistently
present in nuclear-vacuolar junctions. To test whether intact
vacuoles are required to maintain this polarity, we have ana-
FIG. 7. The tsc13 mutant cells have normal condensation activity
but are deficient in total fatty acid chain elongation. (a) Fatty acid
elongation activities in wild-type (wt) and tsc13 mutant microsomes
were compared using C16-, C18-, and C20-CoAs as substrates by mea-
suring the incorporation of radiolabeled malonyl-CoA into hexane-
extractable fatty acids. The assays were conducted in the absence of
NADPH or NADH to measure condensation activity and in the pres-
ence of NADPH or NADH to measure total elongation. Activities are
normalized to the overall activity measured with wild-type microsomes,
using C20-CoA as the substrate. ND, not determined. The assays were
conducted in triplicate, and the results were averaged. The variation
was less than 7%. (b) The elongation assays were conducted as for
panel a, using C16-CoA as the substrate and either wild-type (left) or
tsc13 mutant (right) microsomes. The reactions were stopped at the
indicated times, and the fatty acids were extracted and separated by
TLC. The reactions were conducted with (lanes 1 to 6) or without
(lanes 7 to 12) NADPH or NADH. The positions of the 3-ketostearate
(3-Keto), stearate, trans-2,3-stearate (Trans-2,3), and 3-hydroxystear-
ate (3-Hydroxy) intermediates were determined by running the stan-
dards on the TLC plate and charring after exposure to Phosphor-
Imager screens.
FIG. 8. Tsc13p coimmunoprecipitates with Elo2p and with Elo3p.
Microsomes were prepared from strain TDY2058 cells containing no
tagged proteins (lanes 5 and 9) or the same cells containing only
Myc-tagged Tsc13p (lanes 6 and 10), Myc-tagged Tsc13p and HA-
tagged Elo2p (lanes 1, 3, 7, and 11) or Myc-tagged Tsc13p and HA-
tagged Elo3p (lanes 2, 4, 8, and 12); 10 mg of total microsomal protein
was loaded in lanes 1 and 2. The microsomes were solubilized, and the
100,000 3 g supernatant was used for immunoprecipitation experi-
ments using anti-GST (lanes 3 and 4), anti-HA (lanes 5 to 8), or
anti-Myc (lanes 9 to 12) antibodies. The immunoprecipitated proteins
were separated by SDS-PAGE (12% gel) and analyzed by immuno-
blotting with HRP-conjugated anti-Myc (top panel) or anti-HA (bot-
tom panel) antibodies.
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FIG. 9. (A) C-terminally tagged Tsc13p-GFP shows a typical ER localization pattern and, in addition, is highly enriched in a region of the
nuclear envelope adjacent to the vacuole. Selected cells are shown at higher magnification in the lower panel. (B) Elo2p-GFP, Elo3p-GFP, and
Opi3p-GFP localize to the ER; i.e., around the nucleus and at the cell periphery. a, GFP fluorescence; b, FM4-64-labeled vacuolar membranes;
c, DIC transmission images. Each scale bar is 10 mm.
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FIG. 10. (A) Time course of GAL1P promoter-controlled Elo2p-GFP induction after shift from glucose to galactose-containing medium,
determined at 0, 30, 60, and 120 min. The lower row shows corresponding DIC transmission images. The high background signal at 0 min is due
to the high amplification settings on the microscope and the background fluorescence of the culture medium. (B) Tsc13p-GFP localizes to sites
of nucleus-vacuole interaction in elo2 and elo3 mutants. elo2 and elo3 mutants show multilobed vacuoles; nevertheless, Tsc13p-GFP appears
predominantly at sites between the nuclear envelope and vacuoles. a, GFP fluorescence; b, FM4-64 fluorescence; c, DIC transmission image.
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lyzed Tsc13p-GFP distribution in pep3 mutants which contain
only vestigial nonacidic vacuoles (41, 42). As shown in Fig.
11B, the polarity of Tsc13p-GFP localization on the nuclear
surface is lost in pep3 mutants but still appears somewhat
clustered.
Taken together, the localization data suggest that Tsc13p is
a component of the ER and that its enrichment at the nuclear-
vacuolar interface is dependent on the presence of vacuolar
membranes. The factors establishing this polarized localization
pattern are still obscure but may be dispensable for Tsc13p to
fulfill its essential function.
DISCUSSION
VLCFAs are essential cellular components that are predom-
inantly present in sphingolipids, the lipid moiety of GPI an-
chors, and to some extent in a novel PtdIns species recently
identified in nuclear membrane extracts (51). Based on nuclear
membrane phenotypes associated with reduced synthesis of
C26 in conditional acc1 mutants, a structural role for VLCFA
in stabilizing the highly curved nuclear membrane at the nu-
clear pore complex was postulated (48, 51). The importance of
VLCFAs for cell viability is further demonstrated by the fact
that mutants unable to synthesize sphingolipids produce novel
PtdIns species that contain C26 in the sn-2 position (30). Stud-
ies to determine the structures and organization of the en-
zymes responsible for VLCFA synthesis have only recently
become possible. Multiple elongating systems within the same
organism are apparently responsible for elongating acyl-CoA
substrates with different chain lengths and degrees of unsat-
uration. The identification in S. cerevisiae of three structurally
and functionally related elongase proteins, Elo1p, Elo2p, and
Elo3p, that display different chain length preferences are con-
sistent with this suggestion (37, 59). Since they control the
abundance of fatty acids with different chain lengths, it seems
likely that these proteins participate in the condensation step
FIG. 11. (A) Karmellae are distinctly different from the structures labeled by Tsc13p-GFP. Karmellae form upon overexpression of an
Hmg1p-GFP construct (a, GFP fluorescence); orientation of karmellae localized on the nuclear envelope is always on the opposite site of the
vacuole (b, FM4-64 staining). c, DIC transmission image. (B) Enrichment of Tsc13p-GFP to the sites of nucleus-vacuole interaction depends on
the presence of vacuolar membranes. pep3 mutants contain vestigial vacuoles (b, FM4-64 staining); localization of Tsc13p-GFP appears dispersed
on the surface of the nuclear membrane; polarization of the GFP signal is absent (a). c, DIC transmission image.
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of elongation. However, the yeast Elo proteins have no homol-
ogy to any of the condensing enzymes that have been charac-
terized so far at the molecular level. For example, several
genes encoding putative condensing enzymes of fatty acid elon-
gation have been cloned from plants and have been demon-
strated to stimulate VLCFA synthesis in heterologous expres-
sion systems (29, 32, 33). Interestingly, there are no homologs
of these plant genes in S. cerevisiae, but there are homologs of
the ELO genes in plants.
The characterization of mammalian homologs of the ELO
genes has recently been undertaken (61). One mammalian
homolog (Ssc1) was found to complement the sphingolipid
deficiency of the elo3 mutant, and another (Cig30) reversed the
phenotype of the elo2 mutant. Furthermore, Ssc1 mRNA levels
were reduced in the brains of myelin-deficient mice that are
known to have low fatty acid elongation activity.
In addition to the condensation reaction, a reduction step, a
subsequent dehydration, and a second reduction are required
for fatty acid chain elongation. The studies presented here
demonstrate that the nonredundant TSC13 gene encodes a
protein required for the enoyl reductase activity of fatty acid
elongation. Based on the homology of Tsc13p to steroid-5-a-
reductase, it is likely that Tsc13p is the enoyl reductase enzyme
per se. Tsc13p is a member of a family of proteins that have
been conserved from yeast to mammals. Substitution of the
glutamine with lysine at residue 81 of Tsc13p is responsible for
the ts phenotype conferred by the tsc13-1 mutant allele. This
residue is conserved in all Tsc13p homologs in the database.
The rat TSC13 homolog, SC2, was initially identified as a gene
that is highly expressed in brain, an organ where VLCFA
synthesis is known to occur at high rates.
For the synthesis of long-chain fatty acids up to C16, similar
reactions are catalyzed by the multifunctional cytosolic FAS
complex. Interestingly, none of the FAS domains has any ho-
mology to Elo2p, Elo3p, or Tsc13p. Furthermore, tsc13-1 mu-
tants are not hypersensitive to diazaborin, a drug that inhibits
bacterial enoyl-acyl carrier protein reductase (4), suggesting
different reaction mechanisms for these enzymes.
The incorporation of VLCFA into sphingolipid is catalyzed
by ceramide synthase, which has not been identified yet. In
wild-type cells, VLCFAs are hydroxylated on C-2 by Scs7p
after they are incorporated into ceramide (16, 20). Fatty acids
with chain lengths shorter than C26 are not normally incorpo-
rated into ceramide and are thus not hydroxylated in wild-type
cells. However, in mutants with VLCFA synthesis defects, fatty
acids shorter than C26 are incorporated into ceramide and are
thus subject to hydroxylation by Scs7p. It is interesting that the
elo2D and tsc13-1 mutant cells contained similar levels of the
hydroxylated C26 fatty acid as did wild-type cells, whereas the
overall content of C26 was reduced. Thus, ceramide synthase
appears to have a strong preference for C26 fatty acids but is
also able to modify the fatty acids with chain lengths of less
than C26 that accumulate in elo2 and tsc13-1 mutants. Since in
wild-type cells none of the intermediates of the elongation
reaction appear in hydroxylated form in ceramides, we suggest
a metabolic channeling mechanism for VLCFA synthesis that
would require a concerted action of the elongase complex,
including Elo2, Elo3p, and Tsc13p, prior to incorporation of
VLCFA into sphingolipid by ceramide synthase. Alternatively,
synthesis of the C16- to C24-containing ceramides in the mu-
tants could arise from the reversed activity of the ceramidase
enzyme encoded by YPC1 (condensation of LCBs with free
fatty acids 31) acids rather than from ceramide synthase) (Fig.
1). The reverse ceramidase reaction may be driven by the high
levels of LCBs in the elongase mutants.
Ceramides in yeast are subject to inositolphosphorylation
(an essential process) and subsequent mannosylation, which
represents a nonessential modification to this class of lipids. It
is interesting that the enzymes responsible for mannosylation
of the IPC require a ceramide with a C26 fatty acid and that C24
ceramides accumulating in elongation mutants are not man-
nosylated. The chain length of the fatty acid is apparently also
important for discrimination of IPC from PtdIns, since in slc1
mutants that incorporate C26 fatty acids into PtdIns this phos-
pholipid becomes mannosylated. Thus, the availability of par-
ticular VLCFA species in a lipid appears to determine down-
stream lipid modification processes. Interestingly, recent
studies using fatty acid elongation mutants defective in elo1
suggest that the availability of fatty acids with certain chain
lengths could also be an important determinant of phospho-
lipid composition (50). The molecular mechanisms involved,
however, remain to be determined.
The unique localization of Tsc13p to a specific domain
within the ER membrane at the nuclear-vacuolar interface
raises many questions. It will be interesting to determine
whether this domain of the ER membrane is the site where
VLCFA synthesis occurs. It is possible that other enzymes
required for sphingolipid synthesis, for example, the subunits
of serine palmitoyltransferase or ceramide synthase, reside in
this domain. Based on the experiments described here, this
domain at the nuclear-vacuolar interface is not required for the
function of Tsc13p, but its formation requires interaction with
vacuolar membranes. Only recently, in studies on the localiza-
tion of the vacuolar membrane protein Vac8p, a similar asym-
metric protein distribution was observed at sites of vacuolar-
vacuolar (38, 66) and vacuolar-nuclear envelope (47)
interactions. Polarity of Vac8p to so-called nucleus-vacuole
junctions requires the presence of Nvj1p in the nuclear enve-
lope (39). Similarly, polarized localization of Nvj1p in the nu-
clear envelope depends on the presence of Vac8p. Whether
Tsc13p requires Nvj1p or Vac8p for localization to sites of
nucleus-vacuole interaction remains to be determined. How-
ever, localization of neither Nvj1p, Vac8p, nor Tsc13p to this
domain is essential for viability, since both nvj1 or vac8 mu-
tants and pep3 mutants deficient in vacuolar structures are
viable. Furthermore, enrichment of Tsc13p to this domain is
not dependent on C26 VLCFA since its localization is not
altered in the elo mutants.
What could be the physiological role of the polarized local-
ization of Tsc13p, or of the fatty acid elongation system, to sites
of nuclear-vacuolar interaction? Due to the extended hydro-
phobic chain of VLCFAs, it might be necessary to provide a
protein complex to accommodate these fatty acids in the mem-
brane. Biochemical data as discussed above have already sug-
gested a metabolic channeling mechanism for VLCFA synthe-
sis. The role of vacuoles in this process is not clear. However,
the appearance of vesicles highly enriched in Tsc13p that are
budding off the nuclear membrane into the lumen of the vac-
uole when cells enter stationary phase indicates that a site of
nuclear-vacuolar interaction may be a preferred site of nuclear
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envelope recycling. Thus, the striking nuclear membrane phe-
notype in mtr7 mutants defective in ACC, and thus in fatty acid
chain elongation (48, 49), may be a consequence of perturbed
nuclear membrane recycling to the vacuole.
VLCFAs are essential components of sphingolipids and, due
to the extended hydrophobic chain, represent a major struc-
tural determinant for the membrane harboring these lipids. In
mammalian cells, sphingolipids and cholesterol may assemble
to form lipid rafts, which are characterized as detergent-insol-
uble membrane fractions. Very recently, lipid rafts have also
been identified in yeast, and evidence suggests that certain
secretory proteins, e.g., Pma1p and Gas1p, associate with rafts
at the level of the ER (1). The basis for the formation of
sphingolipid-cholesterol-enriched (detergent-insoluble) do-
mains is not understood, but perhaps these membrane do-
mains are synthesized in the ER membrane as a result of the
enrichment of a specific class of lipid biosynthetic enzymes
within a domain of the membrane. Thus, localized synthesis of
VLCFAs and their incorporation into sphingolipids may lead
to sequestering sterols to form detergent-insoluble membrane
domains at specific sites—the nuclear-vacuolar interface of the
ER. Furthermore, the possibility that a specific class of secre-
tory vesicles buds off from this domain of the ER is raised.
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